Last C$0.11 CAD
Change Today +0.005 / 4.76%
Volume 10.0K
CUR On Other Exchanges
Symbol
Exchange
OTC US
As of 2:15 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

diagnocure inc (CUR) Snapshot

Open
C$0.10
Previous Close
C$0.11
Day High
C$0.11
Day Low
C$0.10
52 Week High
03/11/14 - C$0.21
52 Week Low
12/22/14 - C$0.09
Market Cap
4.7M
Average Volume 10 Days
16.6K
EPS TTM
C$-0.04
Shares Outstanding
43.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DIAGNOCURE INC (CUR)

Related News

No related news articles were found.

diagnocure inc (CUR) Related Businessweek News

No Related Businessweek News Found

diagnocure inc (CUR) Details

DiagnoCure Inc., a life sciences company, develops and commercializes cancer diagnostic tests for the detection and management of cancer. The company primarily focuses on molecular diagnostic tests. It offers PCA3 test for the diagnosis of prostate cancer; and GCC marker, Previstage GCC staging test, GCC monitoring blood test, Shc proteins, and scientific publications for use in colorectal cancer management. The company was founded in 1994 and is headquartered in Quebec, Canada.

10 Employees
Last Reported Date: 01/27/15
Founded in 1994

diagnocure inc (CUR) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: C$180.1K
Interim Chief Financial Officer and Senior Di...
Total Annual Compensation: C$129.7K
Compensation as of Fiscal Year 2013.

diagnocure inc (CUR) Key Developments

DiagnoCure Inc. Announces Earnings Results for the Fourth Quarter and Fiscal Year Ended October 31, 2014

DiagnoCure Inc. announced earnings results for the fourth quarter and fiscal year ended October 31, 2014. The corporation announced a net loss of $461,710 or $0.01 per share for the fourth quarter ended October 31, 2014, compared to $1,334,099 or $0.03 per share for the same period in 2013. Total revenues for the fourth quarter of 2014 were $122,254 compared with $149,465 for the same period of 2013. This decrease of $27,211 or 18% is mostly attributable to PCA3 royalties, reflecting a decrease in royalty revenues from Europe. The company reported net loss of $2,032,151 or $0.05 per share for fiscal year 2014 compared to $3,566,942 or $0.08 per share for the same period in 2013. Total revenues for fiscal 2014 were $553,140 compared with $671,228 for 2013. This decrease of $118,088 or 18% is mainly attributable to PCA3 royalties reflecting a decrease in U.S. royalty revenues.

DiagnoCure Inc. to Report Fiscal Year 2014 Results on Jan 22, 2015

DiagnoCure Inc. announced that they will report fiscal year 2014 results on Jan 22, 2015

DiagnoCure Inc. Reports Consolidated Earnings Results for the Third Quarter Ended July 31, 2014

DiagnoCure Inc. reported consolidated earnings results for the third quarter ended July 31, 2014. For the quarter, the company reported total revenues of $153,424 against $189,585 a year ago. This decrease of $36,161 or 19% is mostly attributable to PCA3 royalties, reflecting a decrease in U.S. royalty revenues. Net loss (before stock-based compensation, depreciation and amortization) was $406,853 against $351,753 a year ago. Net loss and comprehensive loss was $504,105 against $595,262 a year ago. Basic and diluted net loss per share was $0.01 against $0.01 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CUR:CN C$0.11 CAD +0.005

CUR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CUR.
View Industry Companies
 

Industry Analysis

CUR

Industry Average

Valuation CUR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.6x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DIAGNOCURE INC, please visit www.diagnocure.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.